Aidence Overview
Aidence, founded in 2015 and based in Amsterdam, Netherlands, is a company specializing in the development and deployment of AI-powered clinical applications, particularly focused on improving the diagnosis and management of lung cancer through medical image analysis.
Product Overview: Veye Lung Nodules
Aidence’s flagship product, Veye Lung Nodules, is an AI-based solution designed to enhance the detection, measurement, classification, and tracking of pulmonary nodules, which are potential early signs of lung cancer.
Key Features and Functionality
- Automated Detection and Analysis: Veye Lung Nodules automatically detects, measures, and classifies pulmonary nodules from CT scans, reducing the risk of misdiagnosis and ensuring more accurate results.
- Volume Growth Tracking: The system tracks the volume growth of detected nodules over time, providing valuable insights for monitoring and managing lung cancer progression.
- Integration with Clinical Workflow: Veye is integrated into the clinical routine and can be seamlessly connected to hospitals’ Picture Archiving and Communication Systems (PACS) and Radiology Information Systems (RIS) through platforms like Incepto. This integration ensures that the results from the AI tool are returned in a standardized, structured, and editable report.
- Regulatory Compliance: Veye Lung Nodules is CE marked in Europe and is currently used in clinical practice across more than 100 European centers. It is also pending FDA 510(k) clearance for use in the United States.
- Clinical Impact: The solution is a key component of large-scale lung cancer screening programs, such as the UK’s Targeted Lung Health Checks Program, where it has been used to screen over 1 million people. It has also received recognition for improving lung cancer prognosis, including an AI Award to support the UK’s National Health Service.
- Multicountry Presence: Veye Lung Nodules is used by customers in seven European countries, including France, the Netherlands, and the United Kingdom, and is part of RadNet’s broader AI initiatives aimed at enhancing cancer screening programs globally.
Conclusion
In summary, Aidence’s Veye Lung Nodules is a cutting-edge AI solution that empowers radiologists and healthcare professionals to deliver faster, more precise diagnostics and treatments for lung cancer, significantly improving patient outcomes.